August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care

Salvador Payán Pernía/LinkedIn

Aug 21, 2026, 10:23

Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care

Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his colleagues co-authord, published in Emerging Therapeutic, adding:

“The pathophysiology of Sickle Cell Disease (SCD) is so multifaceted, and the heterogeneity of patients’ complication profiles so great, that the path toward optimal pharmacological treatment will likely involve combining different therapies and tailoring treatment to each patient’s individual profile—a profile that we still need to characterize better than we currently can.

The results of the RISE UP study firmly establish mitapivat as a treatment for anemia, one of the defining features of SCD, which can have a substantial negative impact even in patients who do not experience recurrent vaso-occlusive crises.

In this editorial commentary, my colleagues and friends at CIEMAT, José Carlos Segovia Sanz and Isabel Ojeda Pérez, and I reflect on some of the findings from the RISE UP study and discuss what they may mean for the therapeutic positioning of mitapivat in SCD.”

Title: Mitapivat in sickle cell disease: a therapeutic setback or a shift in perspective?

Authors: Salvador Payán-Pernía, Isabel Ojeda-Pérez, Jose-Carlos Seg

Salvador Payán Pernía